Novel Plasminogen Activator Inhibitor-1 Inhibitors Prevent Diabetic Kidney Injury in a Mouse Model

Area of Science:

• Nephrology
• Pharmacology
• Diabetology

Background:

• Diabetic nephropathy is a leading cause of end-stage renal disease globally.
• Plasminogen activator inhibitor-1 (PAI-1) plays a critical role in extracellular matrix accumulation in diabetic kidneys.
• Current therapeutic strategies for diabetic nephropathy are limited.

Purpose of the Study:

• To investigate the renoprotective effects of novel, orally active PAI-1 inhibitors, TM5275 and TM5441.
• To evaluate the efficacy of these compounds in a mouse model of streptozotocin-induced diabetic nephropathy.

Main Methods:

• Administration of TM5275 (50 mg/kg) and TM5441 (10 mg/kg) orally to diabetic mice for 16 weeks.
• Assessment of kidney function markers, including plasma glucose, creatinine, and urinary albumin excretion.
• Histopathological analysis of kidney tissues to evaluate glomerular volume, mesangial expansion, fibrosis, and inflammation.

Main Results:

• Diabetic mice exhibited significantly elevated glucose, creatinine, albuminuria, and kidney damage markers.
• TM5275 and TM5441 treatment effectively reduced albuminuria, mesangial expansion, ECM accumulation, and macrophage infiltration.
• In vitro studies confirmed TM5275 and TM5441 as potent PAI-1 inhibitors, reversing PAI-1-induced effects on fibrosis and inflammation markers.

Conclusions:

• TM5275 and TM5441 demonstrate significant renoprotective effects in a diabetic nephropathy model.
• These PAI-1 inhibitors show potential for preventing or treating diabetic kidney injury.
• The lack of bleeding episodes associated with these compounds is a favorable characteristic for therapeutic development.